Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide



Status:Archived
Conditions:Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen


The study will evaluate the safety and tolerability, optimal biologic dose, and
pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet
count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.



We found this trial at
3
sites
GSK Investigational Site
Anaheim, California 92807
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
GSK Investigational Site
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
GSK Investigational Site
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials